STOCK TITAN
  1. Home
  2. News
  3. UTHR

United Therapeutics Corp - UTHR STOCK NEWS

IMPACT
SENTIMENT
UTHR : Nasdaq
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021
conferences earnings
IMPACT
SENTIMENT
UTHR : Nasdaq
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study
IMPACT
SENTIMENT
MNKD : Nasdaq UTHR : Nasdaq
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA
IMPACT
SENTIMENT
UTHR : Nasdaq MNKD : Nasdaq
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
IMPACT
SENTIMENT
UTHR : Nasdaq LQDA : Nasdaq
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
IMPACT
SENTIMENT
UTHR : Nasdaq
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
clinical trial
IMPACT
SENTIMENT
UTHR : Nasdaq
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
conferences
IMPACT
SENTIMENT
UTHR : Nasdaq
United Therapeutics Corporation Reports First Quarter 2021 Financial Results
earnings
IMPACT
SENTIMENT
UTHR : Nasdaq
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021
conferences earnings
IMPACT
SENTIMENT
UTHR : Nasdaq
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
Stock UTHR logo
United Therapeutics Corp

Nasdaq:UTHR

UTHR Rankings

#903 Ranked by Market Cap
#2304 Ranked by Stock Gains
N/A Ranked by Dividends

UTHR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Silver Spring

About UTHR

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians